Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

r>(unaudited; in thousands, except per share data)Three Months EndedSix Months EndedDec. 31,Sep. 30,Dec. 31,Dec. 31, Dec. 31,20122012201120122011GAAP net income$
41,927$
75,606$
56,253$
7,533$
41,715Adjustments:Research and Development share-based compensation (2)

2,7672,5901,7015,3573,239General and Administrative share-based compensation (2)

1,5035766752,0791,3014,2703,1662,3767,4364,540Non-GAAP net income$
46,197$
78,772$
58,629$
24,969$
46,255GAAP net income per share - basic$
.60$
.09$
.82$
.69$
.61Share-based compensation expense

0.060.040.030.100.07Non-GAAP net income per share - basic$
.66$
.13$
.85$
.79$
.68GAAP net income per share - diluted$
.56$
.02$
.78$
.580.58Share-based compensation expense

0.060.040.040.100.07Non-GAAP net income per share - diluted$
.62$
.06$
.82$
.68$
.65(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance with GAAP.(2) All share-based compensation was excluded for the non-GAAP analysis.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... report commissioned by the U.S. Department of Energy has ... of producing hydrogen fuel from sunlight is the only ... meet future cost targets set by the federal agency. ... Alan Weimer,s research team of CU-Boulder,s chemical and biological ...
... Stem Cell Assurance, Inc. (SCLZ.PK) announced today ... Securities on Form 10 pursuant to Section 12(g) of the ... financial statements as of December 31, 2009 and 2010 and ... July 11, 2011, the Company will become an SEC reporting ...
... Dan Neumeister, FACHE, principal of Neumeister Healthcare Management Services ... selected by Chase Brexton Health Services (CBHS) of Baltimore, ... effective May 1, 2011. Neumeister is serving in this ... fills the position. As CBHS,s top ...
Cached Biology Technology:CU method projected to meet DOE cost targets for solar thermal hydrogen fuel production 2Regional Healthcare Management Firm Goes National 2
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... to drugs, alcohol and tobacco in utero is bad ... have been hard to tease out in humans. Often ... factors like poverty can also influence brain development. ... brain scans, led by Childrens Hospital Boston neurologist Michael ...
... scientists are now flying through springtime Arctic pollution to ... summertime sea ice is melting - faster than predicted. ... university colleagues in Fairbanks, Alaska, to conduct the study ... our eyes, said A.R. Ravishankara, director of the chemistry ...
... Endometriosis is a poorly understood condition that incapacitates and affects ... world. In the US, it affects approximately six million women ... year. It is a chronic painful disease which occurs ... in the area of the ovaries and fallopian tubes, but ...
Cached Biology News:Your baby's brain on drugs (and alcohol and tobacco) 2NOAA aircraft to probe arctic pollution 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
...
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
Biology Products: